Immuno Combos Gain Steam in Blood Cancers

Lauren M. Green and Silas Inman
Published: Friday, Dec 02, 2016
Anas Younes, MD

Anas Younes, MD

Nivolumab (Opdivo) may be the only checkpoint inhibitor that the FDA has approved thus far for a hematologic malignancy, but research is moving forward rapidly across the spectrum of blood cancers with ongoing clinical trials for immunotherapy agents alone and in combination with other novel therapies.

Key researchers in the field provided updates on the evolving landscape for several cancer types during the 34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® that Physicians’ Education Resource (PER®) hosted November 9-11, 2016, in New York City.

Lymphoma

In May, the FDA approved nivolumab as a treatment for patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin (Adcetris).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x